New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
The European Medicines Agency has received 11 new marketing authorization applications, including three for orphan products from Vertex, MYR Pharmaceuticals and AstraZeneca.
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.